News - OBI Pharma 台灣浩鼎

2016.Oct.26

未分類

Corporate

OBI Pharma Sponsors Successful Adagloxad Simolenin (OBI-822) Symposium at ESMO

2016.Sep.06

未分類

Corporate

Legal Statement-OBI’s Attorneys Decide to Take Further Actions against Next Magazine

2016.Sep.06

未分類

Corporate

OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting

2016.Sep.03

未分類

Corporate

Michael Chang: “the U.S. Department of Justice Had Already Proven My Innocence”

2016.Aug.11

未分類

Corporate

Dr. Nathan Chen leaves OBI Pharma; Accepts New Role on Company’s Medical Advisory Board

2016.Jul.27

未分類

Corporate

Quick Takes on Promising New Approaches to Treating Breast Cancer

2016.Jul.26

未分類

Corporate

ASCO KOL interviews: Dr. Hope Rugo／Dr. James C. Paulson

2016.Jun.05

未分類

Corporate

OBI Pharma Presents Data for Novel Investigational OBI-822/OBI-821 in Patients with Metastatic Breast Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

2016.May.19

未分類

Corporate

OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer

2016.May.19

未分類

Corporate

OBI Pharma to Present New Data at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Announcements

Latest announcements

Events

Latest events